Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study

Table 1 Clinical characteristics of 190 patients

Clinical characteristic	No. of patients
Age (yr), median (IQR)	51 (42-58)
Sex
Male, n (%)	154 (81.1)
Etiology
Hepatitis B	144 (75.8)
Hepatitis C	4 (2.1)
Hepatitis B & C	2 (1.1)
Non-hepatitis B, non-hepatitis C	40 (21.0)
ALT (U/L), median (IQR)	75 (51-254)
AST (U/L), median (IQR)	57 (47-302)
TBiL (μmol/L), median (IQR)	20.1 (11.2-31.2)
AFP (ng/mL), median (IQR)	205 (19.2-4692)
Child-Pugh class
A	146 (76.8)
B	44 (23.2)
Portal vein tumor thrombosis	131 (68.9)
Extrahepatic metastasis
Lung	64 (33.7)
Bone	31 (16.3)
Peritoneum	25 (13.1)
Multiple locations	15 (7.9)
BCLC stage
C	190 (100)
Tumor response
Complete response	0 (0)
Partial response	23 (12.1)
Stable disease	76 (40.0)
Progressive disease	91 (47.9)
Follow-up time, median (range)	748 (438-1146) d
TTP, median (95%CI)	98 (75-124) d
OS, median (95%CI)	376 (340-411) d

IQR: Interquartile range; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBiL: Total bilirubin; AFP: Alpha fetoprotein; TTP: Time to progression; OS: Overall survival; BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval.